Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

RCGP demands GP advice on child abuse

Statins are particularly effective at treating coronary risk in patients with kidney disease and could significantly reduce mortality and morbidity, new research suggests.

Treatment with 40mg daily pravastatin reduced the risk of coronary deaths and revascularisations by 23 per cent in patients with moderate kidney disease, according to the international study of 4,491 patients. The drug reduced risk in patients with normal renal function by 22 per cent.

The reduction in absolute risk was greater in patients with kidney disease, whose risk when untreated was 26 per cent higher than in patients with normal renal function.

Researchers from the UK, US, Canada and Australia combined results from three randomised controlled trials as part of the Pravastatin Pooling Project.

Dr John Pittard, board member of the Primary Care Cardiovascular Society and a GP in Staines, Middlesex, said: 'We know a lot of people with renal failure die from coronary artery disease. This study confirms the magic-wand effect of statins in disease involved in the circulatory system.'

The research was published in Circulation (September).

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say